Staff in drug treatment programs are in an optimal position to support the hepatitis C related needs of their patients. To do so effectively, however, staff need to have accurate information about the hepatitis C virus (HCV). This article examines the HCV knowledge of staff (N = 104) in two drug-free and two methadone maintenance treatment programs (MMTPs) in the New York metropolitan area. Five of 20 items on an HCV Knowledge Assessment were not answered correctly by the majority of the participating staff, and total scores on the Assessment averaged 70%, 71%, and 45% among the medically credentialed staff, non-medically credentialed staff in the MMTPs, and non-medically credentialed staff in the drug-free programs, respectively. The majority of those in the latter group had never participated in a training specifically devoted to HCV. Results suggest the need for effective HCV-related training for all staff in drug treatment programs.
Get full access to this article
View all access options for this article.
References
1.
AlterM. J.Kruszon-MoranD.NainanO. V.McQuillanG. M., and GaoF., The Prevalence of Hepatitis C Virus Infection in the United States, 1988 Through 1994, New England Journal of Medicine, 341(8), pp. 556–62, 1999.
2.
AlterM. J. and MoyerL. A., The Importance of Preventing Hepatitis C Virus Infection among Injection Drug Users in the United States, Journal of Acquired Immune Deficiency Syndromes, 18, pp. S6–S10, 1998.
3.
HaganH.ThiedeH.WeissN. S.HopkinsS. G.DuchinJ. S., and AlexanderE. R., Sharing of Drug Preparation Equipment Associated with Hepatitis C Virus Seroconversion in Drug Injectors, American Journal of Public Health, 91, pp. 42–46, 2001.
4.
WilliamsI., Epidemiology of Hepatitis C in the United States, American Journal of Medicine, 107, pp. 2S–9S, 1999.
5.
AlterM. J., Epidemiology of Hepatitis C, Hepatology, 26, pp. 62S–65S, 1997.
6.
HaganH.McGoughJ. P.ThiedeH.WeissN. S.HopkinsS., and AlexanderE. R., Syringe Exchange and Risk of HBV and HCV in Seattle IDUs, American Journal of Epidemiology, 149, pp. 203–213, 1999.
7.
LorvickJ.KralA. H.SealK.GeeL., and EdlinB. R., Prevalence and Duration of Hepatitis C among Injection Drug Users in San Francisco, California, American Journal of Public Health, 91, pp. 46–47, 2001.
8.
McCarthyJ.J. and FlynnN., Hepatitis C in Methadone Maintenance Patients: Prevalence and Public Policy Implications, Journal of Addictive Diseases, 20, pp. 19–31, 2001.
9.
AlterM. J., Prevention of Spread of Hepatitis C, Hepatology, 36(5Suppl 1), pp. S93–S98, 2002.
10.
GarfeinR. S.DohertyM. C.MonterrosoE. R.ThomasD. L.NelsonK. E., and VlahovD., Prevalence and Incidence of Hepatitis C Virus Infection among Young Adult Injection Drug Users, Journal of Acquired Immune Deficiency Syndromes, 18(Suppl 1), pp. S11–S19, 1998.
11.
HahnJ. A.Page-ShaferK.LumP. J.OchoaK., and MossA. R., Hepatitis C Virus Infection and Needle Exchange Use among Young Injection Drug Users in San Francisco, Hepatology, 34, pp. 180–187, 2001.
12.
ThorpeL. E.OuelletL. J.HershowR.BaileyS. L.WilliamsI. T.WilliamsonJ., and MonterrosoE. R., Risk of Hepatitis C Virus Infection among Young Adult Injection Drug Users Who Share Injection Equipment, American Journal of Epidemiology, 155, pp. 645–653, 2002.
13.
RosenbergS. D.GoodmanL. A., and OsherF. C., Prevalence of HIV, Hepatitis B, and Hepatitis C in People with Severe Mental Illness, American Journal of Public Health, 91, pp. 42–46, 2001.
14.
RosenblumA.NuttbrockL.McQuistionH. L.MaguraS., and JosephH., Hepatitis C and Substance Use in a Sample of Homeless People in New York City, Journal of Addictive Diseases, 20(4), pp. 15–25, 2001.
15.
TortuS.NeaigusA.McMahonJ., and HagenD., Hepatitis C among Non-Injecting Drug Users: A Report, Substance Use and Misuse, 36, pp. 523–534, 2001.
16.
Centers for Disease Control and Prevention, Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease, Morbidity and Mortality Weekly Reports, 47, pp. 1–39, 1998.
17.
FreemanA. J.DoreG. J.LawM. G.ThorpeM.Von OverbeckJ.LloydA. R.MarinosG., and KaldorJ. M., Estimating Progression to Cirrhosis in Chronic Hepatitis C Virus Infection, Hepatology, 34(4 Pt 1), pp. 809–816, 2001.
18.
LiangT. J.RehermannB.SeeffL. B., and HoofnagleJ. H., Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C, Annals of Internal Medicine, 132, pp. 296–305, 2000.
19.
BhopaleG. M. and NandaR. K., Prospects for Hepatitis C Vaccine, Acta Virologica, 48(4), pp. 215–221, 2004.
20.
Di BisceglieA. M. and HoofnagleJ. H., Optimal Therapy of Hepatitis C, Hepatology, 36, pp. S121–S127, 2002.
21.
FriedM. W.ShiffmanM. L.ReddyK. R.SmithC.MarinosG.GoncalesF. L.Jr.HaussingerD.DiagoM.CarosiG.DhumeauxD.CraxiA.LinA.HoffmanJ., and YuJ., Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection, New England Journal of Medicine, 347(13), pp. 975–982, 2002.
22.
BestD.NobleA.FinchE.GossopM.SidwellC., and StrangJ., Accuracy of Perceptions of Hepatitis B and C Status: Cross Sectional Investigation of Opiate Addicts in Treatment, British Medical Journal, 319, pp. 290–291, 1999.
23.
DavisM.RhodesT., and MartinA., Preventing Hepatitis C: ‘Common Sense’, ‘the Bug’ and Other Perspectives from the Risk Narratives of People Who Inject Drugs, Social Science and Medicine, 59(9), pp. 1807–1818, 2004.
24.
DhopeshV. P.TaylorK. R., and BurkeW. M., Survey of Hepatitis B and C in an Addiction Treatment Unit, American Journal of Drug and Alcohol Abuse, 26(4), pp. 703–707, 2000.
25.
HeimerR.ClairS.GrauL. E.BluthenthalR. N.MarshallP. A., and SingerM., Hepatitis-Associated Knowledge is Low and Risks are High among HIV-Aware Injection Drug Users in Three US Cities, Addiction, 97(10), pp. 1277–1287, 2002.
26.
KwiatkowskiC. F.CorsiK. F., and BoothR. E., The Association between Knowledge of Hepatitis C Virus Status and Risk Behaviors in Injection Drug Users, Addiction, 97, pp. 1289–1294, 2002.
27.
RhodesT.DavisM., and JuddA., Hepatitis C and Its Risk Management among Drug Injectors in London: Renewing Harm Reduction in the Context of Uncertainty, Addiction, 99(5), pp. 621–633, 2004.
28.
SteinM. D.MaksadJ., and ClarkeJ., Hepatitis C Disease among Injection Drug Users: Knowledge, Perceived Risk and Willingness to Receive Treatment, Drug and Alcohol Dependence, 61, pp. 211–215, 2001.
29.
WalleyA. Y.WhiteM.SongY.KushellM., and TulskyJ. P., Women Methadone Clients are Less Knowledgeable about Hepatitis C Treatment. Poster presented at the sixty-fifth annual scientific meeting of the College on Problems of Drug Dependence, Bal Harbour, FL., June 16, 2003.
30.
NicklinD. E.SchultzC.BrensingerC. M., and WilsonJ. P., Current Care of Hepatitis C-Positive Patients By Primary Care Physicians in an Integrated Delivery System, Journal of the American Board of Family Practitioners, 12(6), pp. 497–500, 1999.
31.
CoppolaA. G.KarakousisP. C.MetzD. C.GoM. F.MhokashiM.HowdenC. W.RaufmanJ. P., and SharmaV. K., Hepatitis C Knowledge among Primary Care Residents: Is Our Teaching Adequate for the Times?American Journal of Gastroenterology, 99(9), pp. 1720–1725, 2004.
32.
FischerL. R.ConboyK. S.TopeD. H., and ShewmakeD. K., Educating Health Professionals: A Hepatitis C Educational Program in a Health Maintenance Organization, American Journal of Managed Care, 6, pp. 1029–1036, 2000.
33.
ShehabT. M.SonnadS. S., and LokA. S. F., Management of Hepatitis C by Primary Care Physicians in the USA: Results of a National Survey. Journal of Viral Hepatitis, 8, pp. 377–383, 2001.
34.
SmithC. A.JohnsonM., and BrownL. S., Hepatitis C Knowledge Base of Providers Caring for HIV Positive Communities of Color [Abstract 902], 39th Annual Meeting of the Infectious Diseases Society of America, October 25–28, 2001, San Francisco, Calif.
35.
CroftsN.LouieR., and LoffB., The Next Plague: Stigmatization and Discrimination Related to Hepatitis C Virus Infection in Australia, Health and Human Rights, 2(2), pp. 87–97, 1997.
36.
DayC.RossJ., and DolanK., Hepatitis C-Related Discrimination among Heroin Users in Sydney: Drug User or Hepatitis C Discrimination?Drug and Alcohol Review, 22(3), pp. 317–321, 2003.
37.
EdlinB. R.SealK. H.LorvickJ.KralA. H.CiccaroneD. H.MooreL. D., and LoB., Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?New England Journal of Medicine, 345, pp. 211–215, 2001.
38.
StephensonJ., Former Addicts Face Barriers to Treatment for HCV, Journal of the American Medical Association, 285(8), pp. 1003–1005, 2001.
39.
TreloarC.J.HopwoodM. N., and LovedayS. K., Hepatitis C-Related Discrimination in Healthcare. Report of the Third Australasian Conference on Hepatitis C, Melbourne, March 2002, Medical Journal of Australia, 177(5), pp. 233–234, 2002.
40.
ZickmundS.HillisS. L.BarnettM. J.IppolitoL., and LaBrecqueD. R., Hepatitis C Virus-Infected Patients Report Communication Problems with Physicians, Hepatology, 39, pp. 999–1007, 2004.
41.
ZickmundS.HoE. Y.MasudaM.IppolitoL., and LaBrecqueD. R., “They Treated Me Like a Leper.” Stigmatization and the Quality of Life of Patients with Hepatitis C, Journal of General Internal Medicine, 18(10), pp. 835–844, 2003.
42.
D'AunnoT.VaughnT. E., and McElroyP., An Institutional Analysis of HIV Prevention Efforts by the Nation's Outpatient Drug Abuse Treatment Units, Journal of Health and Social Behavior, 40, pp. 175–192, 1999.
43.
GourevitchM. N.WassermanW.PaneroM. S., and SelwynP. A., Successful Adherence to Observed Prophylaxis and Treatment of Tuberculosis among Drug Users in a Methadone Program, Journal of Addictive Diseases, 15(1), pp. 93–104, 1996.
44.
SambamoorthiU.WarnerL. A.CrystalS., and WalkupJ., Drug Abuse, Methadone Treatment, and Health Services Use among Injection Drug Users with AIDS, Drug and Alcohol Dependence, 60, pp. 77–89, 2000.
45.
SorensenJ. L.MassonC. L., and PerlmanD. C., HIV/Hepatitis Prevention in Drug Abuse Treatment Programs: Guidance from Research, Science and Practice Perspectives, 1, pp. 4–11, 2002.
46.
Astone-TwerellJ. M.StraussS. M.HaganH., and Des JarlaisD. C., Providing Support to Drug Users Infected with Hepatitis C: The Role of Methadone Maintenance Treatment Staff, Journal of Maintenance in the Addictions, 3(1), pp. 33–46, 2005.
47.
McCoyH. V.MessiahS. E., and ZhaoW., Improving Access to Primary Health Care for Chronic Drug Abusers: An Innovative Systematic Intervention for Providers, The Journal of Behavioral Health Services and Research, 29, pp. 445–457, 2002.
48.
MorrisonD. S.GilchristG., and AhmedS., Potential of Specialist Drug Services to Deliver Hepatitis B Vaccination, Communicable Diseases and Public Health, 5(4), pp. 321–323, 2002.
49.
StraussS. M.AstoneJ. M.Munoz-PlazaC.HaganH., and Des JarlaisD. C., Residential Drug Treatment Programs as Venues for HCV Pharmacological Treatment: Client and Staff Perspectives, Substance Use and Misuse, 40(12), pp. 1811–1829, 2005.
50.
MillerW. R.BenefieldG., and ToniganJ., Enhancing Motivation for Change in Problem Drinking: A Controlled Comparison of Two Therapist Styles, Journal of Consulting and Clinical Psychology, 61, pp. 455–461, 1993.
51.
ZwebenJ. E., Hepatitis C: Education and Counseling Issues, Journal of Addictive Diseases, 20(1), pp. 33–42, 2001.
52.
LandonB. E.WilsonI. B.WengerN. S.CohnS. E.FichtenbaumC. J.BozzetteS. A.ShapiroM. F., and ClearyP. D., Specialty Training and Specialization Among Physicians Who Treat HIV/AIDS in the United States, Journal of General Internal Medicine, 17(1), pp. 12–22, 2002.
53.
PrattC.-C. N. U.PaoneD.CarterB. J., and LaytonM. C., Hepatitis C Screening and Management Practices: A Survey of Drug Treatment and Syringe Exchange Programs in New York City, American Journal of Public Health, 92, pp. 1254–1256, 2002.
54.
StraussS. M.AstoneJ.VassilevZ. P.Des JarlaisD. C., and HaganH., Gaps in the Drug-Free and Methadone Treatment Program Response to Hepatitis C, Journal of Substance Abuse Treatment, 24(4), pp. 291–297, 2003.
55.
StraussS. M.FalkinG. P.VassilevZ.Des JarlaisD. C., and AstoneJ., A Nationwide Survey of Hepatitis C Services Provided by Drug Treatment Programs, Journal of Substance Abuse Treatment, 22(2), pp. 55–62, 2002.
56.
ChitwoodD. D.McBrideD. C.FrenchM. T., and ComerfordM., Health Care Need and Utilization: A Preliminary Comparison of Injection Drug Users, Other Illicit Drug Users, and Nonusers, Substance Use and Misuse, 34(4–5), pp. 727–746, 1999.
57.
TortuS.McMahonJ.PougetE., and HamidR., Sharing of Non-Injection Drug Use Implements as a Risk Factor for Hepatitis C, Substance Use and Misuse, 39(2), pp. 211–224, 2004.
